![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FZR1 |
Gene summary for FZR1 |
![]() |
Gene information | Species | Human | Gene symbol | FZR1 | Gene ID | 51343 |
Gene name | fizzy and cell division cycle 20 related 1 | |
Gene Alias | CDC20C | |
Cytomap | 19p13.3 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9UM11 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51343 | FZR1 | LZE4T | Human | Esophagus | ESCC | 7.08e-03 | 7.87e-02 | 0.0811 |
51343 | FZR1 | LZE7T | Human | Esophagus | ESCC | 2.86e-05 | 2.48e-01 | 0.0667 |
51343 | FZR1 | LZE20T | Human | Esophagus | ESCC | 3.99e-04 | 1.56e-01 | 0.0662 |
51343 | FZR1 | LZE24T | Human | Esophagus | ESCC | 8.00e-05 | 1.53e-01 | 0.0596 |
51343 | FZR1 | LZE21T | Human | Esophagus | ESCC | 3.73e-05 | 3.56e-01 | 0.0655 |
51343 | FZR1 | P1T-E | Human | Esophagus | ESCC | 6.13e-14 | 4.88e-01 | 0.0875 |
51343 | FZR1 | P2T-E | Human | Esophagus | ESCC | 1.25e-14 | 1.52e-01 | 0.1177 |
51343 | FZR1 | P4T-E | Human | Esophagus | ESCC | 1.29e-12 | 1.95e-01 | 0.1323 |
51343 | FZR1 | P5T-E | Human | Esophagus | ESCC | 1.98e-19 | 2.15e-01 | 0.1327 |
51343 | FZR1 | P8T-E | Human | Esophagus | ESCC | 9.67e-17 | 1.86e-01 | 0.0889 |
51343 | FZR1 | P9T-E | Human | Esophagus | ESCC | 4.48e-09 | 2.44e-01 | 0.1131 |
51343 | FZR1 | P10T-E | Human | Esophagus | ESCC | 2.55e-15 | 2.58e-01 | 0.116 |
51343 | FZR1 | P11T-E | Human | Esophagus | ESCC | 8.78e-05 | 2.97e-01 | 0.1426 |
51343 | FZR1 | P12T-E | Human | Esophagus | ESCC | 4.23e-13 | 2.27e-01 | 0.1122 |
51343 | FZR1 | P15T-E | Human | Esophagus | ESCC | 1.87e-08 | 1.34e-01 | 0.1149 |
51343 | FZR1 | P16T-E | Human | Esophagus | ESCC | 1.97e-09 | 7.37e-02 | 0.1153 |
51343 | FZR1 | P17T-E | Human | Esophagus | ESCC | 3.21e-04 | 3.49e-01 | 0.1278 |
51343 | FZR1 | P20T-E | Human | Esophagus | ESCC | 3.36e-03 | 1.19e-01 | 0.1124 |
51343 | FZR1 | P21T-E | Human | Esophagus | ESCC | 4.27e-12 | 1.09e-01 | 0.1617 |
51343 | FZR1 | P22T-E | Human | Esophagus | ESCC | 2.25e-14 | 7.95e-02 | 0.1236 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00447744 | Oral cavity | OSCC | mitotic DNA integrity checkpoint | 52/7305 | 85/18723 | 2.86e-05 | 2.64e-04 | 52 |
GO:00447734 | Oral cavity | OSCC | mitotic DNA damage checkpoint | 50/7305 | 81/18723 | 2.87e-05 | 2.64e-04 | 50 |
GO:0051783 | Oral cavity | OSCC | regulation of nuclear division | 78/7305 | 139/18723 | 3.13e-05 | 2.86e-04 | 78 |
GO:1902749 | Oral cavity | OSCC | regulation of cell cycle G2/M phase transition | 59/7305 | 102/18723 | 8.81e-05 | 6.72e-04 | 59 |
GO:00075698 | Oral cavity | OSCC | cell aging | 73/7305 | 132/18723 | 1.05e-04 | 7.75e-04 | 73 |
GO:0010972 | Oral cavity | OSCC | negative regulation of G2/M transition of mitotic cell cycle | 38/7305 | 60/18723 | 1.17e-04 | 8.46e-04 | 38 |
GO:1902750 | Oral cavity | OSCC | negative regulation of cell cycle G2/M phase transition | 39/7305 | 62/18723 | 1.19e-04 | 8.54e-04 | 39 |
GO:190466619 | Oral cavity | OSCC | regulation of ubiquitin protein ligase activity | 18/7305 | 23/18723 | 1.47e-04 | 1.04e-03 | 18 |
GO:0031145 | Oral cavity | OSCC | anaphase-promoting complex-dependent catabolic process | 16/7305 | 21/18723 | 5.99e-04 | 3.39e-03 | 16 |
GO:0044818 | Oral cavity | OSCC | mitotic G2/M transition checkpoint | 28/7305 | 46/18723 | 2.19e-03 | 9.95e-03 | 28 |
GO:0007095 | Oral cavity | OSCC | mitotic G2 DNA damage checkpoint | 21/7305 | 34/18723 | 6.02e-03 | 2.28e-02 | 21 |
GO:0010498113 | Thyroid | PTC | proteasomal protein catabolic process | 297/5968 | 490/18723 | 4.58e-40 | 9.63e-37 | 297 |
GO:0043161113 | Thyroid | PTC | proteasome-mediated ubiquitin-dependent protein catabolic process | 254/5968 | 412/18723 | 3.91e-36 | 4.54e-33 | 254 |
GO:0009896113 | Thyroid | PTC | positive regulation of catabolic process | 278/5968 | 492/18723 | 3.35e-30 | 2.64e-27 | 278 |
GO:0031331113 | Thyroid | PTC | positive regulation of cellular catabolic process | 249/5968 | 427/18723 | 5.28e-30 | 3.58e-27 | 249 |
GO:0042176113 | Thyroid | PTC | regulation of protein catabolic process | 231/5968 | 391/18723 | 4.76e-29 | 2.14e-26 | 231 |
GO:1903362113 | Thyroid | PTC | regulation of cellular protein catabolic process | 162/5968 | 255/18723 | 1.62e-25 | 5.12e-23 | 162 |
GO:1903050113 | Thyroid | PTC | regulation of proteolysis involved in cellular protein catabolic process | 140/5968 | 221/18723 | 4.63e-22 | 1.01e-19 | 140 |
GO:1903320113 | Thyroid | PTC | regulation of protein modification by small protein conjugation or removal | 148/5968 | 242/18723 | 4.49e-21 | 8.10e-19 | 148 |
GO:0045732113 | Thyroid | PTC | positive regulation of protein catabolic process | 142/5968 | 231/18723 | 1.43e-20 | 2.38e-18 | 142 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa041108 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
hsa0412020 | Oral cavity | OSCC | Ubiquitin mediated proteolysis | 105/3704 | 142/8465 | 1.83e-13 | 4.37e-12 | 2.23e-12 | 105 |
hsa0411015 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
hsa04120110 | Oral cavity | OSCC | Ubiquitin mediated proteolysis | 105/3704 | 142/8465 | 1.83e-13 | 4.37e-12 | 2.23e-12 | 105 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FZR1 | SNV | Missense_Mutation | novel | c.668N>A | p.Cys223Tyr | p.C223Y | Q9UM11 | protein_coding | deleterious(0) | probably_damaging(0.95) | TCGA-E2-A14N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
FZR1 | deletion | Frame_Shift_Del | c.1328delN | p.Tyr444ThrfsTer24 | p.Y444Tfs*24 | Q9UM11 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | |||
FZR1 | SNV | Missense_Mutation | novel | c.823N>A | p.Gly275Arg | p.G275R | Q9UM11 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FZR1 | SNV | Missense_Mutation | c.1135N>C | p.Asp379His | p.D379H | Q9UM11 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-DG-A2KL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
FZR1 | SNV | Missense_Mutation | c.313N>A | p.Glu105Lys | p.E105K | Q9UM11 | protein_coding | tolerated(0.33) | benign(0.015) | TCGA-EK-A2RN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
FZR1 | SNV | Missense_Mutation | c.661N>T | p.Arg221Trp | p.R221W | Q9UM11 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
FZR1 | SNV | Missense_Mutation | rs754635012 | c.778G>A | p.Ala260Thr | p.A260T | Q9UM11 | protein_coding | tolerated(0.39) | benign(0.006) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FZR1 | SNV | Missense_Mutation | rs760461120 | c.494N>A | p.Arg165Gln | p.R165Q | Q9UM11 | protein_coding | tolerated(0.16) | benign(0.006) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
FZR1 | SNV | Missense_Mutation | c.718C>T | p.Arg240Trp | p.R240W | Q9UM11 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
FZR1 | SNV | Missense_Mutation | c.1466T>A | p.Leu489His | p.L489H | Q9UM11 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-F4-6463-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |